CN114569477A - Non-therapeutic use of DSF as cosmetic additive or cosmetic and cosmetic - Google Patents
Non-therapeutic use of DSF as cosmetic additive or cosmetic and cosmetic Download PDFInfo
- Publication number
- CN114569477A CN114569477A CN202210318618.7A CN202210318618A CN114569477A CN 114569477 A CN114569477 A CN 114569477A CN 202210318618 A CN202210318618 A CN 202210318618A CN 114569477 A CN114569477 A CN 114569477A
- Authority
- CN
- China
- Prior art keywords
- cosmetic
- dsf
- skin
- inflammatory
- additive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 56
- 239000000490 cosmetic additive Substances 0.000 title claims abstract description 22
- 206010061218 Inflammation Diseases 0.000 claims abstract description 23
- 230000004054 inflammatory process Effects 0.000 claims abstract description 19
- 230000036542 oxidative stress Effects 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 239000000839 emulsion Substances 0.000 claims description 21
- 239000006071 cream Substances 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000006210 lotion Substances 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- SNTXNGAQYNSTHI-LUAWRHEFSA-N cis-11-Methyl-2-dodecenoic acid Chemical compound CC(C)CCCCCCC\C=C/C(O)=O SNTXNGAQYNSTHI-LUAWRHEFSA-N 0.000 claims description 6
- 210000004400 mucous membrane Anatomy 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 241000589636 Xanthomonas campestris Species 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000012228 culture supernatant Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 18
- 210000000440 neutrophil Anatomy 0.000 abstract description 16
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 14
- 230000006907 apoptotic process Effects 0.000 abstract description 14
- -1 small molecule compound Chemical class 0.000 abstract description 12
- 230000003078 antioxidant effect Effects 0.000 abstract description 9
- 230000006378 damage Effects 0.000 abstract description 7
- 210000001339 epidermal cell Anatomy 0.000 abstract description 5
- 230000005012 migration Effects 0.000 abstract description 5
- 238000013508 migration Methods 0.000 abstract description 5
- 230000007115 recruitment Effects 0.000 abstract description 5
- 239000003963 antioxidant agent Substances 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 2
- 241000252212 Danio rerio Species 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 23
- 210000002257 embryonic structure Anatomy 0.000 description 15
- 230000004792 oxidative damage Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 8
- 102000016938 Catalase Human genes 0.000 description 7
- 108010053835 Catalase Proteins 0.000 description 7
- 210000004927 skin cell Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 230000006399 behavior Effects 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 4
- LEEDMQGKBNGPDN-UHFFFAOYSA-N 2-methylnonadecane Chemical compound CCCCCCCCCCCCCCCCCC(C)C LEEDMQGKBNGPDN-UHFFFAOYSA-N 0.000 description 4
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 230000037307 sensitive skin Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 3
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- YCUVUDODLRLVIC-VPHDGDOJSA-N sudan black b Chemical compound C1=CC(=C23)NC(C)(C)NC2=CC=CC3=C1\N=N\C(C1=CC=CC=C11)=CC=C1\N=N\C1=CC=CC=C1 YCUVUDODLRLVIC-VPHDGDOJSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 2
- 229940043375 1,5-pentanediol Drugs 0.000 description 2
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 2
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical compound C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940051250 hexylene glycol Drugs 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 2
- 229940078546 isoeicosane Drugs 0.000 description 2
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000011506 response to oxidative stress Effects 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 229940012831 stearyl alcohol Drugs 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000012178 vegetable wax Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010051841 Exposure to allergen Diseases 0.000 description 1
- 101000715499 Homo sapiens Catalase Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000045501 human CAT Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Abstract
The present application relates to the non-therapeutic use of a small molecule compound DSF as a cosmetic additive or cosmetic for preventing and/or inhibiting oxidative stress, and/or inflammatory reaction, and to cosmetics. The cosmetic disclosed by the application can obviously reduce the level of apoptosis on cells and reduce the recruitment and migration behavior of neutrophils to an inflammation part; on the other hand, the antioxidant capacity and the proliferation activity of human epidermal cells can be improved, so that the DSF has good anti-inflammatory and antioxidant activity and has an application prospect for developing cosmetics with anti-inflammatory and antioxidant effects. Moreover, DSF can exert its anti-inflammatory and antioxidant activities at an extremely low dose, which does not cause secondary damage to organisms, and can be produced at a low cost, as compared with other cosmetic additives.
Description
Technical Field
The invention relates to a non-therapeutic use of DSF as a cosmetic additive or cosmetic and a cosmetic, belonging to the field of cosmetics.
Background
The skin, the largest organ that covers the surface of the human body, is the natural barrier of the human body surface. Sensitive skin is defined as skin that is erythematous due to various factors such as physical (uv, heat, cold and wind), chemical (cosmetics, soaps, pollution), pressure or hormones, as well as feeling burning, stinging and itching. Sensitive skin is a common phenomenon in modern society where cosmetics and toiletries are used in large quantities.
Facial skin exhibits unique functional properties in daily life and is also a common site of sensitive skin. Common forms of facial dermatitis include adverse effects such as inflammation and sunburn caused by long-term exposure to Ultraviolet (UV) light from the sun, and allergic contact dermatitis caused by contact with cosmetics. Skin is damaged by ultraviolet radiation and exposure to allergens and bacterial infections, and cells produce oxidative stress and cause massive infiltration of immune cells, such as neutrophils and macrophages, which live in the skin, causing skin inflammation. The key problem to be solved by searching for a proper cosmetic additive is how to comprehensively consider the anti-inflammatory and antioxidant effects, is suitable for sensitive skin, does not stimulate the skin, and causes secondary damage to the skin.
Disclosure of Invention
The purpose of the present invention is to provide a non-therapeutic use of DSF as a cosmetic additive or cosmetic, and a cosmetic, which can alleviate adverse inflammatory reactions of the skin caused by exposure to solar ultraviolet radiation, skin chemicals, and the like, and can prevent and/or inhibit oxidative stress, thereby having an antioxidant effect.
In order to achieve the purpose, the invention provides the following technical scheme:
in a first aspect, the present application provides the non-therapeutic use of DSF as a cosmetic additive or makeup for preventing and/or inhibiting oxidative stress, and/or inflammatory response.
As one example, the DSF is the main effective component of the cosmetic additive or the cosmetic, is derived from Xanthomonas campestris and is obtained by extracting from the supernatant of overnight culture with ethyl acetate, and has a structural formula of cis-11-methyl-2-dodecenoic acid:
as one example, the cosmetic additive or cosmetic is applied to the skin and/or mucous membranes of an animal.
As one example, the DSF can reduce the occurrence of apoptosis and oxidative stress at sites of inflammation.
As one example, the DSF can inhibit the accumulation of neutrophils at the site of inflammation.
In a second aspect, the present application provides a cosmetic comprising, as a cosmetic raw material, DSF which is a main active ingredient, wherein the DSF is cis 11-methyl-2-dodecenoic acid:
as one example, the DSF is present in the cosmetic raw material in an amount of 0.02 to 0.06% by mass.
As one example, the cosmetic may further include excipients and diluents acceptable to mammalian skin and/or mucous membranes, as known to those skilled in the art, and may include, but are not limited to, water; a vegetable oil; mineral oil; esters such as octyl palmitate, isopropyl myristate and isopropyl palmitate; ethers such as dioctyl ether and dimethyl isosorbide ester; alcohols such as ethanol and isopropanol; fatty alcohols such as cetyl alcohol, cetearyl alcohol, stearyl alcohol and benzil alcohol; isoparaffins such as isooctane, isododecane, and isohexadecane; silicone oils such as cyclomethicone, dimethicone crosspolymer, polysiloxane and derivatives thereof, preferably organically modified derivatives; hydrocarbon oils such as mineral oil, vaseline oil, isoeicosane and polyisobutylene; polyols such as propylene glycol, glycerin, butylene glycol, pentylene glycol, and hexylene glycol; waxes, such as beeswax and vegetable waxes; or any combination or mixture of the foregoing.
Further, the vehicle may also comprise an emulsion. Non-limiting examples of suitable emulsions include water-in-oil emulsions, oil-in-water emulsions, silicone-in-water emulsions, water-in-silicone emulsions, wax-in-water emulsions, water-oil-water triple emulsions, and the like, which have the appearance of a cream, gel, or microemulsion. The emulsion may include an emulsifier, such as a nonionic or anionic or amphoteric surfactant.
As one example, the cosmetic may be formulated in various product forms, such as lotions, creams, serums, sprays, aerosols, compact discs, ointments, essential oils, gels, pastes, patches, color pens, towelettes, masks, sticks, foams, elixirs, concentrates, and the like, suitable for topical administration. Further, formulated into lotion, cream, ointment or gel.
As one example, the cosmetic is selected from one or more of a lotion, an emulsion, a serum, a cream, or a foundation.
As one example, the cosmetic may further comprise adjuvants such as surfactant, skin penetration enhancer, antiseptic, antioxidant, humectant, essence, perfume, etc.
In a third aspect, the present application provides a non-therapeutic method of treating human skin for preventing and/or inhibiting oxidative stress, and/or inflammatory response, comprising the step of applying an effective amount of said cosmetic to the human skin.
Compared with the prior art, the invention has the beneficial effects that:
the application provides the application of the DSF as a cosmetic additive or a cosmetic, which can obviously reduce the apoptosis level and reduce the recruitment and migration behavior of neutrophils to an inflammation part, and shows that the DSF has good anti-inflammatory activity and has an application prospect for developing anti-inflammatory cosmetics. Meanwhile, DSF can reduce oxidative stress of skin cells and recover the proliferative activity of the skin cells, thereby protecting the skin cells and playing a role in resisting oxidation. Also, DSF can exert its anti-inflammatory activity at an extremely low dose, which does not cause secondary damage to organisms, and can be produced at low cost, as compared with other cosmetic additives or cosmetics.
The foregoing description is only an overview of the technical solutions of the present invention, and in order to make the technical solutions of the present invention more clearly understood and to implement them in accordance with the contents of the description, the following detailed description is given with reference to the preferred embodiments of the present invention and the accompanying drawings.
Drawings
FIG. 1 is a graph of Sudan Black B staining and neutrophil quantification of three groups of zebrafish embryos, as shown in an example of the present application;
FIG. 2 is a graph of acridine orange staining and apoptotic cell quantification of three groups of zebrafish embryos, as shown in an example of the present application;
FIG. 3 is a schematic representation of three sets of human immortalized epidermal cell activity assays according to one embodiment of the present application;
FIG. 4 shows three groups of human immortalized epidermal cell catalase activity assays according to an embodiment of the present application.
Detailed Description
The following detailed description of the present invention is provided in connection with the accompanying drawings and examples. The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially. The procedures, conditions, reagents, experimental methods and the like for carrying out the present invention are general knowledge and common general knowledge in the art, except for those specifically mentioned below, and the present invention is not particularly limited.
By "statistically significant" is meant that the change is greater than would be expected by chance alone (may be a "false positive"). Statistical significance can be determined by any method known in the art. A commonly used measure of significance includes a p-value, which represents the probability that at least a threshold value will yield a result at a given data point, assuming that the data point is a single contingent result. The p value is 0.05 or less, and the results are generally considered to be highly significant.
In a first aspect, the present application provides the non-therapeutic use of DSF as a cosmetic additive or makeup for preventing and/or inhibiting oxidative stress, and/or inflammatory response.
Optionally, the DSF is a major active ingredient of the cosmetic additive or cosmetic, and the DSF is cis 11-methyl-2-dodecenoic acid:
optionally, the cosmetic additive or cosmetic is applied to the skin and/or mucous membranes of the animal.
Alternatively, the DSF is derived from xanthomonas campestris and is obtained by extraction from the overnight culture supernatant with ethyl acetate.
DSF can regulate and control the formation of bacterial biomembrane and reduce the expression of virulence genes of pathogenic bacteria, and can effectively inhibit the colonization of pathogenic bacteria. In the experimental process, the inventor finds that the DSF can obviously inhibit the recruitment and migration behaviors of neutrophils to an inflammation part caused by the fact that an inflammatory agent induces the skin inflammation of the zebra fish, and recovers the reduction of the proliferation activity and the catalase activity of human skin cells caused by UVB irradiation, so that the inflammation injury is relieved, the oxidative stress reaction is prevented and/or inhibited, and the anti-inflammatory and antioxidant effects are achieved. Therefore, the DSF can be used as a cosmetic additive to play the roles of resisting inflammation and oxidation.
In addition, the inventor also finds that the apoptosis level of the skin inflammation model cell of the zebra fish treated by the DSF has the tendency of obviously recovering to the normal level, so the invention also provides that the DSF has the function of resisting apoptosis and can play a role in repairing inflammation injury.
Alternatively, the DSF may reduce the occurrence of apoptosis and oxidative stress at the site of inflammation.
Alternatively, the DSF may inhibit the accumulation of neutrophils at the site of inflammation.
In a second aspect, the present application provides a cosmetic comprising, as a cosmetic raw material, DSF which is a main active ingredient, wherein the DSF is cis 11-methyl-2-dodecenoic acid:
alternatively, the DSF is present in the cosmetic raw material in an amount of 0.02 to 0.06% by mass, at which the inventors found that it exerts its anti-inflammatory activity without causing secondary damage to the organism.
Optionally, the cosmetic further comprises excipients and diluents acceptable to the skin and/or mucous membranes of animals, known to those skilled in the art, and may include, but are not limited to, water; a vegetable oil; mineral oil; esters, such as octyl palmitate, isopropyl myristate and isopropyl palmitate; ethers such as dioctyl ether and dimethyl isosorbide ester; alcohols such as ethanol and isopropanol; fatty alcohols such as cetyl alcohol, cetearyl alcohol, stearyl alcohol and benzil alcohol; isoparaffins such as isooctane, isododecane, and isohexadecane; silicone oils such as cyclomethicone, dimethicone crosspolymer, polysiloxane and derivatives thereof, preferably organically modified derivatives; hydrocarbon oils such as mineral oil, vaseline oil, isoeicosane and polyisobutylene; polyhydric alcohols such as propylene glycol, glycerin, butylene glycol, pentylene glycol, and hexylene glycol; waxes, such as beeswax and vegetable waxes; or any combination or mixture of the foregoing.
Optionally, the excipient may also comprise an emulsion. Non-limiting examples of suitable emulsions include water-in-oil emulsions, oil-in-water emulsions, silicone-in-water emulsions, water-in-silicone emulsions, wax-in-water emulsions, water-oil-water triple emulsions, and the like, which have the appearance of a cream, gel, or microemulsion. The emulsion may include an emulsifier, such as a nonionic or anionic or amphoteric surfactant.
Alternatively, the cosmetic may be formulated in various product forms, such as lotions, creams, serums, sprays, aerosols, pressed powders, ointments, essential oils, gels, pastes, patches, color pens, towelettes, masks, sticks, foams, elixirs, concentrates, and the like, suitable for topical administration. Further, formulated into lotion, cream, ointment or gel.
Optionally, the cosmetic is selected from one or more of a lotion, an emulsion, a serum, a cream or a foundation.
Optionally, the cosmetic may also contain adjuvants such as surfactant, skin penetration enhancer, antiseptic, antioxidant, humectant, essence, and perfume.
In a third aspect, the present application provides a non-therapeutic method of treating human skin for preventing and/or inhibiting oxidative stress, and/or inflammatory response, comprising the step of applying an effective amount of said cosmetic to the human skin. By applying or topically applying a cosmetic to human skin, oxidative stress and/or inflammatory reactions can be prevented and/or inhibited while achieving normal cosmetic effects.
The following is a further description with reference to specific examples.
Example one test of the inhibition of DSF on the accumulation of inflammatory agents in the embryonic neutrophils in zebrafish
1. Roe collection
Selecting healthy adult zebra fish in the evening before the day, wherein the weight ratio of male fish to female fish is 1: 1, inserting a baffle in the middle of the mating box, and pulling out the baffle every morning. The embryos were collected in petri dishes, added with embryo medium and cultured in a constant temperature incubator at 28.5 ℃.
2. Skin inflammation model construction and DSF treatment
The zebrafish embryos were divided into three groups, a control group, a model group and an experimental group. The control group is only treated by using a normal culture medium, a proper amount of an inflammation-causing agent is added into the model group, and the experiment group is co-treated by adding the inflammation-causing agent and DSF. After each group of zebra fish is treated to 3dpf, zebra fish embryos are collected to prepare for detecting neutrophils.
3. Detection of zebra fish embryonic neutrophils
The collected zebrafish embryos of each group were washed three times with fresh embryo culture medium and fixed overnight with 4% paraformaldehyde. After washing the embryos with PBST, the embryos were stained with Sudan black B staining solution for 30min, washed with 70% ethanol, and observed with a microscope every 15min during washing until the staining was clearly visible. Then, ethanol was washed away with PBST, sudan black B stained particles in neutrophils, black spots on zebrafish skin observed under a microscope aggregated into stained neutrophils, and migration recruitment behavior and aggregation number of cells were recorded.
The experimental results are as follows:
as shown in FIG. 1, the model group showed a marked increase in neutrophils on the skin and aggregation behavior (# p < 0.05, # p < 0.01, # p < 0.001) after addition of the inflammatory agent compared to the control group, and a marked decrease in the number of neutrophils accumulated on the skin of zebrafish after addition of the DSF compared to the model group (p < 0.05, # p < 0.01, # p < 0.001) with statistical differences. The DSF can inhibit the neutrophil aggregation caused by inflammation and has anti-inflammatory activity.
Example two detection of the inhibitory Effect of DSF on inflammatory agent-induced apoptosis of zebrafish embryonic cells
1. Roe collection
Selecting healthy adult zebra fish in the evening before the day, wherein the weight ratio of male fish to female fish is 1: 1, inserting a baffle plate in the middle of the mating box, and pulling out the baffle plate every morning. The embryos were collected in petri dishes, added with embryo medium and cultured in a constant temperature incubator at 28.5 ℃.
2. Skin inflammation model construction and DSF treatment
The zebrafish embryos were divided into three groups, a control group, a model group and an experimental group. The control group is only treated by using a normal culture medium, a proper amount of an inflammation-causing agent is added into the model group, and the experiment group is co-treated by adding the inflammation-causing agent and DSF. And (3) when each group of zebra fish is processed to 4dpf, collecting zebra fish embryos and preparing for detecting apoptosis.
3. Detection of zebra fish embryonic cell apoptosis
The collected groups of zebrafish embryos were washed twice with fresh embryo medium and stained with acridine orange to detect apoptotic cells in 4dpf zebrafish embryos. Zebra fish embryos are incubated for 30 minutes at room temperature in 10. mu.g/mL acridine orange staining solution protected from light. After washing 3 times with fresh embryo medium, the number of apoptosis was observed under a fluorescence microscope.
The experimental results are as follows:
as shown in fig. 2, the number of fluorescent stained particles in the zebrafish embryos of the model group was significantly increased after induction of the inflammatory response compared to the control group (# p < 0.05, # p < 0.01, # p < 0.001), indicating that the cells were significantly apoptotic, and the number of apoptotic cells in the zebrafish was significantly decreased after addition of DSF compared to the model group, with a statistical difference (# p < 0.05, # p < 0.01, # p < 0.001). The DSF can reduce apoptosis caused by inflammation and has anti-inflammatory activity.
EXAMPLE three examination of the effect of DSF on human immortalized epidermal cell Activity after UV irradiation
1. Cell culture
HaCaT cells are cultured by DMEM containing 10% calf serum, 1% penicillin and 1% streptomycin under the conditions of 37 ℃, 5% CO2 and relative saturation humidity for 2-3 d passages, and cells in a logarithmic growth phase are taken for testing.
2. Taking HaCaT cells in logarithmic growth phase, and adjusting the cell density to be 5 multiplied by 104And (4) inoculating the cells/mL into a 96-well plate, wherein each well is 200 mu L, and randomly dividing the cells into a normal control group, an oxidative damage group and a DSF experimental group after culturing for 24 hours. Appropriate amount of UVB simulation in oxidative damage groupUltraviolet irradiation, and simulating oxidation apoptosis at a cell level.
3. DSF experimental groups DSF treatment was added after UVB irradiation induced oxidative damage to cells.
4. MTT method for measuring cell proliferation activity
Discarding the culture solution, washing with PBS, adding 100 μ L MTT solution with concentration of 0.5mg/L into each well, incubating for 4h, carefully absorbing the liquid in each well, adding 150 μ L DMMSO into each well, shaking for 10min, measuring the light absorption value of each well under 490nm wavelength of an enzyme labeling instrument, and calculating the cell proliferation activity according to the formula. Cell proliferation activity ═ oxidative damage group or DSF experimental group/normal control group × 100%.
Referring to fig. 3, the results showed that the proliferative activity of cells in the DSF experimental group had a clear tendency to return to normal levels (# p < 0.05, # p < 0.01, # p < 0.001, # p < 0.05, # p < 0.01, # p < 0.001) compared to the oxidative damage group.
Example four testing of the effect of DSF on Catalase Activity in human immortalized epidermal cells after UV irradiation
1. Cell culture
HaCaT cells are cultured by DMEM containing 10% calf serum, 1% penicillin and 1% streptomycin under the conditions of 37 ℃, 5% CO2 and relative saturation humidity for 2-3 d passages, and cells in a logarithmic growth phase are taken for testing.
2. Taking HaCaT cells in logarithmic growth phase, and adjusting the cell density to be 5 multiplied by 104And (4) inoculating the cells/mL into a 96-well plate, wherein each well is 200 mu L, and randomly dividing the cells into a normal control group, an oxidative damage group and a DSF experimental group after culturing for 24 hours. The oxidative damage group simulates oxidative apoptosis at the cellular level using a suitable amount of UVB to simulate ultraviolet radiation.
3. DSF experimental groups DSF treatment was added after UVB irradiation induced oxidative damage to cells.
4. Determination of catalase activity by kit
The cells of each group were harvested, centrifuged to discard the supernatant, washed with PBS and diluted to 1X 106cell/mL cell solution, repeatedly freezing and thawing to prepare cell pulp, centrifuging to obtain cell supernatant, and determining peroxide according to the specification of a human Catalase (CAT) enzyme-linked immunoassay kitCatalase activity, 3 replicates.
Referring to fig. 4, the results show that catalase activity of cells of the oxidative damage group is significantly reduced compared to the normal control group; compared with the oxidative damage group, the catalase activity of the DSF experimental group cells is obviously improved. Indicating an increased resistance to oxidative damage (# p < 0.05, # p < 0.01, # p < 0.001, # p < 0.05, # p < 0.01, # p < 0.001).
In summary, the following steps:
the application provides the application of the DSF as a cosmetic additive or a cosmetic, which can obviously reduce the apoptosis level and reduce the recruitment and migration behavior of neutrophils to an inflammation part, and shows that the DSF has good anti-inflammatory activity and has an application prospect for developing anti-inflammatory cosmetics. Meanwhile, DSF can reduce oxidative stress of skin cells and recover the proliferative activity of the skin cells, thereby protecting the skin cells and playing a role in resisting oxidation. Also, DSF can exert its anti-inflammatory activity at an extremely low dose, which does not cause secondary damage to organisms, and can be produced at low cost, as compared with other cosmetic additives or cosmetics.
All possible combinations of the technical features of the above embodiments may not be described for the sake of brevity, but should be considered as within the scope of the present disclosure as long as there is no contradiction between the combinations of the technical features.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
- Non-therapeutic use of DSF as a cosmetic additive or makeup, characterized in that said cosmetic additive or makeup is used to prevent and/or inhibit oxidative stress, and/or inflammatory reactions.
- 2. Use according to claim 1, wherein said DSF is the cosmetic additive or the major active ingredient of a cosmetic product, said DSF being cis 11-methyl-2-dodecenoic acid:
- 3. use according to claim 1, characterized in that the cosmetic additive or cosmetic is applied to the skin and/or mucous membranes of animals.
- 4. Use according to claim 1, wherein said DSF is derived from xanthomonas campestris and is obtained by extraction from the overnight culture supernatant with ethyl acetate.
- 5. A cosmetic characterized by comprising, as a cosmetic raw material, DSF as a main active ingredient, wherein DSF is cis-11-methyl-2-dodecenoic acid:
- 6. the cosmetic according to claim 5, wherein the mass fraction of the DSF in the cosmetic raw material is 0.02 to 0.06%.
- 7. The cosmetic of claim 5, further comprising excipients and diluents acceptable to the skin and/or mucous membranes of animals.
- 8. The cosmetic of claim 5, wherein the cosmetic is a lotion, cream, ointment, or gel.
- 9. The cosmetic of claim 8, wherein the cosmetic is selected from one or more of a lotion, an emulsion, a serum, a cream, or a foundation.
- 10. A method of non-therapeutic treatment of human skin for preventing and/or inhibiting oxidative stress, and/or inflammatory reactions, comprising the step of applying to human skin an effective amount of a cosmetic product according to any one of claims 5 to 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210318618.7A CN114569477A (en) | 2022-03-29 | 2022-03-29 | Non-therapeutic use of DSF as cosmetic additive or cosmetic and cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210318618.7A CN114569477A (en) | 2022-03-29 | 2022-03-29 | Non-therapeutic use of DSF as cosmetic additive or cosmetic and cosmetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114569477A true CN114569477A (en) | 2022-06-03 |
Family
ID=81776068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210318618.7A Pending CN114569477A (en) | 2022-03-29 | 2022-03-29 | Non-therapeutic use of DSF as cosmetic additive or cosmetic and cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114569477A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110123462A1 (en) * | 2009-11-23 | 2011-05-26 | Mcneil-Ppc, Inc. | Biofilm disruptive compositions |
| CN114306307A (en) * | 2022-01-20 | 2022-04-12 | 西安英创生物技术有限公司 | Application of DSF in preparing anti-inflammatory drugs or anti-oxidation drugs and drugs |
-
2022
- 2022-03-29 CN CN202210318618.7A patent/CN114569477A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110123462A1 (en) * | 2009-11-23 | 2011-05-26 | Mcneil-Ppc, Inc. | Biofilm disruptive compositions |
| CN114306307A (en) * | 2022-01-20 | 2022-04-12 | 西安英创生物技术有限公司 | Application of DSF in preparing anti-inflammatory drugs or anti-oxidation drugs and drugs |
Non-Patent Citations (2)
| Title |
|---|
| YANG DONG LIANG等: "Protective Effects of cis-2-Dodecenoic Acid in an Exp、rimental Mouse Model of Vaginal Candidiasis", 《BIOMED ENVIRON SCI》, vol. 31, no. 11, pages 816 - 828 * |
| 席丽艳等: "《常见真菌感染性疾病直接镜检图谱》", 广东科技出版社, pages: 35 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100435855B1 (en) | Composition for external application to the skin containing Opuntia ficus-indica extract | |
| CN108294992A (en) | A kind of acne-removing composition | |
| CN110327228A (en) | A kind of suncream | |
| KR101352363B1 (en) | Composition of skin external application for moisturizing comprising Scrophularia buergeriana Miq. extract | |
| CN110946784A (en) | Skin care composition with functions of improving skin barrier function and enhancing skin health | |
| CN109620840A (en) | A kind of pharmaceutical composition and its application of anti-skin photoage | |
| CA2909573A1 (en) | Use of barrier biomarkers for evaluating the effectiveness of active ingredients | |
| CN112263493B (en) | Sunscreen composition, sunscreen gel containing sunscreen composition and preparation method of sunscreen gel | |
| CN109431910A (en) | Skin barrier remediation composition and its application | |
| CN109431913A (en) | Skin microecological balance composition and application thereof | |
| CN114569477A (en) | Non-therapeutic use of DSF as cosmetic additive or cosmetic and cosmetic | |
| JPH0249710A (en) | Cosmetic | |
| CN115414308B (en) | Acne-removing composition, preparation method and application | |
| KR20210090870A (en) | Cosmetic composition with excellent skin barrier using skin microbiome | |
| KR101611976B1 (en) | Cosmetic Composition containing minerals of volcanic stone extracts for improving skin troubles | |
| JPH04282321A (en) | Cosmetic | |
| CN101099719A (en) | Extraction of limnocitrus littoralis and use thereof in cosmetic compositions | |
| JP2002047188A (en) | INHIBITOR OF LOWERING OF EXPRESSION OF beta- GLUCOCEREBROSIDASE GENE | |
| US20150104426A1 (en) | Skin-care agent containing pleurotus ferulae fruit body extract or pleurotus ferulae mycelium extract | |
| CN112237552B (en) | Skin external preparation composition containing composite hyaluronic acid | |
| KR100769577B1 (en) | Cosmetic Composition against Aging of the Skin | |
| KR100769579B1 (en) | Cosmetic composition against aging of the skin | |
| Faggi et al. | Anti‐Malassezia furfur antibodies in the population: Anti‐Malassezia furfur Antikörper in der Bevölkerung | |
| JPH04282320A (en) | Cosmetic | |
| CN114668682B (en) | Moisturizing and skin-brightening composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |